myocardium and improving the clinical symptoms of heart failure [5] . Therefore, the attention of many researchers has been long-focused on extra-cardiac stem cells with the ability, at least in principle, to differentiate into the cardiac muscle phenotype [6] . In this context, stem cell grafting for cardiac repair is viewed as the new frontier in the treatment of post-infarction heart failure [7] [8] [9] . Skeletal myoblasts, for example, have been considered promising candidates [10] , mainly because they are resistant to ischaemia and hence may survive within the poorly vascularized myocardial scar. Further, these cells can be isolated and expanded ex vivo from skeletal muscle biopsies of the same patients scheduled for cell grafting therapy, with obvious immunological and ethical advantages [6, 10] . Although engrafted skeletal myoblasts do not exhibit the potential to differentiate into myocardial-like cells [11] , numerous studies have demonstrated a significant improvement of the heart's contractile performance upon myoblast transplantation [12, 13] . A possible explanation for this ostensible paradox has come from the results of recent experimental studies, suggesting that the grafted cells may release paracrine cardiotropic factors capable of inducing collagen remodelling and neoangiogenesis in the recipient hearts [14, 15] .
Based on the above-reported observations, it appears that further investigations are needed to shed light on the mechanisms underlying the functional advantages of myoblast grafting in the post-ischaemic heart and to better define the possible therapeutic protocols. A novel approach may be the combination of myoblast cell grafting and cellular therapy, whereby cells can act as carriers for genes encoding cardiotropic substances that
can be delivered locally [10] . Indeed, a recent study from our group showed that the cardiotropic hormone relaxin (RLX) is capable of improving the contractile performance of postinfarcted swine hearts by positively influencing cardiac remodelling and neo-angiogenesis [15] . RLX is a member of a peptide hormone family, which includes three distinct RLX molecules (denoted H1, H2 and H3, respectively) , as well as insulin-like peptides (INSL) 3 to 6 [16, 17] . In human beings, three separate RLX genes have been found and designated RLN1, RLN2 and RLN3 [16, 17] . [17] [18] [19] [20] [21] [22] and exerts major effects on the cardiovascular system [17, 21, 22] . Some of these effects, namely increased heart perfusion [23] , neo-angiogenesis [24] and reduced cardiac fibrosis by increased extracellular matrix (ECM) turnover [25] 18 fluorodeoxyglucose ( 18 F-FDG), as previously described [31, 32] . 18 
(H2), encoded by the RLN2 gene, is the major circulating form and accounts for most of the known biological effects of RLX in human beings and experimental animals. RLX acts on both reproductive and non-reproductive tissues

Surgery and experimental protocols
Echocardiographic assessment of cardiac function
FS; (iv) left ventricular ejection fraction, LVEF; (v) myocardial performance index, MPI, the sum of isovolumetric contraction and relaxation times/ejection time. This assay was carried out prior (T0) and 1 month after (T1) the induction of myocardial infarction, as well as 1 (T2) and 2 (T3) months after DMEM, RLX or cell delivery.
Micro-PET analysis of myocardial viability and performance
Positron emission tomography (PET) scans on the rats of the different groups were performed after administration of the viability tracer
Determination of cycling cardiac cells
Results
Echocardiography
In all the animals, surgical induction of myocardial infarction caused a marked decay of the assayed echocardiographic parameters of cardiac function. Namely, 1 month after surgery (T1), LVEF and FS were significantly reduced, whereas LVEDD, LVESD and MPI were significantly increased in comparison with the preoperative (T0) values (Fig. 1). In the untreated controls (group 1), these parameters remained substantially unchanged in the successive measurements carried out 1 month (T2) and 2 months (T3) after re-operation, at variance with significant improvements in the rats subjected to the therapeutic treatments. In particular, (i) LVEF was significantly increased in the rats which received C2C12/GFP (group 3) and even more in those which received C2C12/RLXϩRLX (group 4); (ii) FS was significantly increased in the rats given both RLX alone (group 2) and C2C12/RLXϩRLX (group 4) at T2, and in all the treated animal groups at T3: at both time-points, the best performance was achieved by the rats of group 4; (iii) LVEDD and LVESD were significantly reduced in all the treated animal groups at T2 and even more at T3; LVEDD was similarly improved in all the three groups, whereas LVESD was particularly reduced in the animals receiving C2C12 engraftment; (iv) MPI were significantly and similarly reduced in all the treated animal groups at T2 and even more at T3.
Micro-PET analysis
Quantitative tomographic analysis of cardiac 18 F-FDG uptake showed that, 1 month after surgical induction of myocardial infarction (T1), the rats of all the experimental groups had a marked reduction of the overall volume of viable myocardium (Fig. 2). In many cases, this viability defect, appearing as a hypo-metabolic, radio-negative region, involved the antero-septal left ventricular wall and was substantially similar in all the animals examined. Treatment with C2C12/RLXϩRLX induced a clearcut, statistically significant increase (P Ͻ 0.01) in the volume of viable myocardium as early as 1 month after cell grafting (T2) and even more at 2 months (T3), accounting for an increase of 16% and 31%, respectively, over the values measured at T1. On the other hand, treatment with C2C112/GFP
only significantly increased the viability of the myocardium at T3 (P Ͻ 0.05), whereas RLX alone had little or no effect on this parameter. 
Localization of the grafted cells in the host hearts
Relatively few immunoreactive eGFP-expressing C2C12 were found in the scar tissue from groups 3 and 4 ( Fig. 3A and B 
Histological features of post-infarcted hearts
By modified Azan staining (Fig. 4, upper panels) (Fig. 4, centre panel) . By TEM (Fig. 4, lower (Fig. 5) .
Determination of apoptotic and proliferating cardiac cells
To provide further insight into the mechanisms of the observed improvement of the post-infarcted hearts subsequent to therapeutic treatments, we examined and quantified the amount of apoptotic and cycling cells in the myocardium surrounding the scar. By TUNEL assay (Fig. 6) [10, 33, 34] . The current findings also indicate that RLX can be an effective agent in protecting the post-infarcted heart from adverse remodelling, in keeping with the emerging concept that this hormone, due to its collagen-remodelling, pro-angiogenic and vasodilatatory properties [23] [24] [25] , can play a major cardioprotective role [17, 21, 22, 34] . This study confirms and extends our previous findings obtained by transplantation of RLX-producing C2C12 cells in postinfarcted swine, examined 1 month after cell injection [15] [35] . Considering the effects of exogenously given RLX observed in animal models of acute myocardial infarction [36, 37] [38, 39] . This is consistent with the recent 'paracrine' hypothesis to explain the functional benefits of stem cell therapy in the post-infarcted, dysfunctional heart [14, 15, 33, 34, 40] .
Plasma RLX levels
The [15] and can be conceivably explained by the lack of appropriate micro-environmental signals in a non-physiological host tissue [41] . This finding offers additional support to the concept that transplanted myoblasts can improve the function of post-infarcted heart by indirect mechanisms, independent of de novo regeneration of contractile tissue [7, 8, 14, 34] [42] . The current findings also point to the option of using delayed rather than immediate cell therapy following acute myocardial infarction to achieve better efficacy, in keeping with previous reports [43] .
